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The aim of this study is to analyse whether immunohistochemistry (IHC) applying a broad set of markers could be used to categorise
ductal carcinoma in situ (DCIS) of the breast in distinct subgroups corresponding to the recently defined molecular categories of
invasive carcinoma. Immunohistochemistry of pure DCIS cases constructed in tissue arrays was performed with 16 markers
(oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), Bcl-2, p53, Her2, insulin-like growth factor receptor,
E-cadherin, epithelial membrane antigen (EMA), CA125, keratins 5/6, 14, 19, epidermal growth factor receptor, S100, and CD31).
Results in 163 cases were analysed by unsupervised hierarchical clustering. Histological classification was performed by review of
whole tissue sections and identified 36 well-, 55 intermediately, and 72 poorly differentiated DCISs. Unsupervised hierarchical cluster
analysis categorised DCIS into two major groups that could be further subdivided into subgroups based on the expression of six
markers (ER, PR, AR, Bcl-2, p53, and Her2). In the major predominantly ER/Bcl-2-positive (luminal) group, three subgroups (AR-
positive (n¼33), AR-negative (n¼40), and mixed (n¼34)) could be identified and included 34 well-differentiated DCISs. Within
the major predominantly ER/Bcl-2-negative (nonluminal) group, a Her2-positive subgroup (n¼34) was characterised by 31 poorly
differentiated lesions. Eight triple-negative lesions, including one positive for keratin 5/6 and two positive for p53, were encountered.
Intermediately differentiated DCIS shared a comparable IHC staining pattern with well-differentiated DCIS that was distinct from
poorly differentiated DCIS (Po0.001). Ductal carcinoma in situ could be categorised by IHC into two major groups and five
subgroups using six markers. Morphologically, intermediately differentiated DCIS seems to have more biological similarities with
well-differentiated lesions as compared to poorly differentiated lesions.
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Breast cancer encompasses a heterogeneous group of tumours,
which vary in morphology, clinical presentation, and behaviour.
Traditionally, breast cancers are morphologically typed according
to the World Health Organization (WHO) guidelines. The latest
classification recognises at least 30 different invasive tumour types
(World Health Organization Classification of Tumours, 2003).
There is no consensus about the classification of the noninvasive
precursor of breast carcinoma, ductal carcinoma in situ (DCIS). As
in other areas of pathology, a three-tier system is most often used,
based on growth pattern and cytonuclear criteria, and dividing
DCIS into well-, intermediately, and poorly differentiated subtypes
(Holland et al, 1994). In prospective studies, this classification has
proven value in risk assessment of recurrence after breast-
conserving treatment and progression into invasive carcinoma
(Bijker et al, 2006). However, inter- and intraobserver variability is
a problem inherent to morphologic tumour classification and
grading (Sloane et al, 1998); moreover, heterogeneity within DCIS
lesions is not uncommon, resulting in variation in grade (Ma et al,
2003). Perou et al (2000) suggested a categorisation of invasive
breast cancers based on genetic profiles into oestrogen receptor
(ER)-positive (luminal A and B) and ER-negative (nonluminal)
subtypes with a further subdivision of the ER-negative types into
Her2-positive and basal-like subtypes. Luminal A tumours differ
from luminal B tumours by a higher expression of ER-related
genes and lower expression of proliferation-associated genes. It
was possible to make the same categorisation by immunohisto-
chemistry (IHC) using markers aimed at luminal, Her2, and basal-
like features (Makretsov et al, 2004). The objective of this study is
to classify DCIS by marker expression to improve the current
morphological classifications and gain insight into the biology
underlying the heterogeneity in DCIS. Therefore, tissue micro-
arrays were constructed from a series of pure DCISs, a large set
of markers were used for IHC, and unsupervised hierarchical
cluster analysis was performed to evaluate results; clustering was
correlated with morphologic grade of DCIS as assessed on whole
tumour slides.
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Tissue microarray sections were constructed taking three 0.6-mm
tissue cores per case, from formalin-fixed, paraffin-embedded
tumour blocks with pure DCIS of 238 patients using a tissue-
arraying instrument (Beecher Instruments, Silver Spring, MD,
USA). Immunohistochemistry was performed on an automated
stainer after pretreatment in the autoclave in citrate buffer at pH
6.0 according to standardised protocols for the different antibodies
at prescribed dilutions (see Table 1). Sixteen markers were used
including ER, progesterone receptor (PR), androgen receptor
(AR), Her2, Bcl-2, p53, E-cadherin, epidermal growth factor
receptor, insulin-like growth factor receptor, CD31, keratin 5/6,
keratin 14, keratin 19, S100, epithelial membrane antigen (EMA),
and CA125. The selection of antibodies was based on recent
investigations in gene signature profiles in invasive breast cancer,
suitability for DCIS, and availability. Staining results were semi-
quantitatively scored according to the criteria in Table 1. The
higher IHC score was considered as a final score in case of a
difference between tissue cores. Cutoff points are shown in Table 1
and were directed to detect luminal and nonluminal (sub)groups.
All cases were classified as well-, intermediately, and poorly
differentiated on the whole tumour slides according to the
classification of Holland et al (1994); in case of heterogeneity,
the highest grade was used for analysis. The distribution of
markers and histological grade among (sub)groups was analysed
using the w
2-test or Fisher’s exact test. Tests were two-tailed and
the significance level was taken 5%. Discriminative markers
underwent unsupervised hierarchical clustering analysis with
average and complete linkage (Genesis 1.5.0; IGB-TUG, Graz,
Austria) to organise tissue microarray score data into meaningful
structures, in accordance with the more complex method used for
cDNA microarrays (Weigelt et al, 2005). The impact of the markers
on hierarchical cluster group results was investigated to define a
final set of markers for IHC classification. Correlation between
markers was determined using the Spearman’s correlation
coefficient. The agreement in classification of cases based on
different hierarchical clustering methods (average linkage vs
complete linkage) and different IHC classifications were assessed
with the k-statistic. A k-value of 0.41–0.6 was considerate
moderate agreement, 0.61–0.8 substantial agreement, and more
than 0.8 near-perfect agreement. All analyses were performed in
SPSS
s 11.5 for Windows (SPSS, Chicago, IL, USA).
RESULTS
Of the 238 DCIS samples, 27 (11%) did not contain tumour and 48
(20%) had incomplete IHC data due to loss of tissue. All analyses
were performed on the remaining 163 cases. Median age of these
patients was 50 years (range: 28–82 years). Seventy-three per cent
of the lesions were screen detected. Histological classification
identified 36 (22%) well-, 55 (34%) intermediately, and 72 (44%)
poorly differentiated lesions.
Marker expression in DCIS
Table 2 presents the distribution of the different markers in DCIS.
Oestrogen receptor and PR were most frequently present in well-
and intermediately differentiated DCIS (Po0.001), whereas Her2
expression was most frequently found in poorly differentiated
DCIS (Po0.001). Also, Bcl-2 and p53 expression was different
among grades: well-differentiated DCIS were often Bcl-2 positive
and p53 negative compared to poorly differentiated DCIS. Thirty-
three out of thirty-six well-differentiated DCISs stained positive
for Bcl-2 compared to 26 out of 72 poorly differentiated DCISs
(Po0.001). Further, all well-differentiated DCISs were p53
negative, while half of the poorly differentiated lesions were p53
positive (Po0.001). Moderately differentiated DCIS formed an
intermediate group in expression of these markers with the
exception of AR. This marker was found positive in 28
intermediately differentiated DCISs compared to 13 well-differ-
entiated and 19 poorly differentiated DCISs (P¼0.018). The
remaining markers showed no statistically significant association
with grade of DCIS. The E-cadherin protein could be detected in all
DCISs, while markers for EGFR, CD31, keratin 14, S100, and
CA125 showed negative staining results in all lesions. insulin-like
growth factor receptor, keratin 19, and EMA were found positive in
nearly all DCISs except seven DCISs. Five out of these seven DCISs
were poorly differentiated. Three poorly differentiated DCISs
showed staining for keratin 5/6.
IHC categorisation by unsupervised hierarchical analysis
Unsupervised hierarchical clustering analysis was applied to the
IHC data set. On the basis of the expression of ER and Bcl-2, the
clustergram in Figure 1 shows two major groups: a predominantly
ER/Bcl-2-positive (luminal) and a predominantly ER/Bcl-2-negative
Table 1 List of antibodies and tissue microarray scoring criteria
Marker Clone Source Dilution Staining pattern Cutoff point
1 ER 1D5+6F11 Neomarker 1:50 Nuclear Any +
2 PR PR-1 ImmunoVision 1:500 Nuclear Any +
3 AR AR441 Neomarker 1:400 Nuclear Strong 410%
4 Her2 3B5 Neomarker 1:80000 Membranous Strong 410%
5 Bcl-2 124 DAKO 1:400 Cytoplasmic Weak 410%
6 p53 DO-7 DAKO 1:1000 Nuclear 425%
7 E-cadherin HECD-1 Intermedico/Zymed 1:2500 Membranous Weak 410%
8 EGFR 111.6 Neomarker 1:200 Membranous Strong 410%
9 IGFR 24–31 Neomarker 1:100 Cytoplasmic and membranous Weak 410%
10 CD31 JC/70A DAKO 1:50 Cytoplasmic Any +
11 Keratin 5/6 D5/16B4 DAKO 1:200 Cytoplasmic Any +
12 Keratin 14 LL002 Neomarker 1:200 Cytoplasmic Any +
13 Keratin 19 RB-9021
a Neomarker 1:200 Cytoplasmic Weak 410%
14 S100 Z0311
a DAKO 1:4000 Cytoplasmic Any +
15 EMA E29 DAKO 1:1000 Cytoplasmic and membranous Weak 410%
16 CA125 BGX324A Biogenex 1:80 Membranous Weak 410%
AR¼androgen receptor; EGFR¼epidermal growth factor receptor; EMA¼epithelial membrane antigen; ER¼oestrogen receptor; IGFR¼insulin-like growth factor receptor;
PR¼progesterone receptor. DAKO, Glostrup, Denmark; Neomarker, Fremont, CA, USA; Intermedico/Zymed, San Francisco, CA, USA; ImmunoVision, Springdale, AR, USA;
and Biogenex, San Ramon, CA, USA.
aCatalogue number.
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using other marker results. The luminal group demonstrated
a completely AR-positive subgroup (n¼33), a completely AR-
negative subgroup (n¼40), and a mixed subgroup of AR-positive
and -negative lesions (n¼34), while the nonluminal group
included a completely Her2-positive cluster (n¼34). The luminal
lesions included 34 (94%) well-differentiated, 46 (84%) inter-
mediately differentiated, and 27 (38%) poorly differentiated DCISs.
These poorly differentiated DCISs lesions showed markers positive
for ER (all 27), Bcl-2 (n¼25), PR (n¼14), Her2 (n¼12), AR
(n¼9), and p53 (n¼4).
The nonluminal subgroups had 45 poorly differentiated DCISs
and 11 nonpoorly differentiated lesions including nine with
intermediately and two with well-differentiated DCISs. These 11
lesions showed a marker pattern that was positive for ER (n¼2),
Bcl-2 (n¼1), Her2 (n¼7), AR (n¼5), and p53 (n¼2). In total,
eight ER-negative, PR-negative, and Her2-negative lesions, includ-
ing one positive for keratin 5/6 and two positive for p53, were
found. Table 3 shows the comparison of the distribution of
histological grade among the identified subgroups. Intermediately
differentiated DCIS significantly more often shared IHC features
with well-differentiated DCIS than with poorly differentiated DCIS
(Po0.001).
Reproducibility of cluster groups
For the assessment of variation in clustering results when using
different hierarchical clustering methods, unsupervised hierar-
chical clustering by complete linkage was performed on the
classification set of six markers. The concordance between
designation of individual cases to one of the subgroups using
average linkage vs complete linkage showed a near-perfect
agreement (k¼0.876), with 16 mismatches out of 163 paired cases.
Comparison with IHC categorisation based on genetic
profiles
A comparison of our results with the earlier findings from Perou
et al (2000) based on genetic profiles of invasive breast carcinoma
is shown in Table 4. A classification of DCIS lesions into luminal
A, luminal B, Her2, and basal-like subtypes was performed on
the staining results of three markers (ER, PR, and Her2) and
was compared with the findings of the present study. Both
classifications showed a moderate agreement (k¼0.411) mainly
caused by the differentiation of the luminal types into A and B. If
both the luminal types are considered as one group, the
classifications demonstrated a substantial agreement (k¼0.649).
Table 2 Expression of markers in well-, intermediately, and poorly differentiated DCIS
Histological grade (%)
Type and marker Total (%) Well, n¼36 (22) Intermediate, n¼55 (34) Poor, n¼72 (44) P
ER 111 (68) 34 (94) 47 (86) 30 (42) o0.001
PR 75 (46) 26 (72) 33 (60) 16 (22) o0.001
AR 60 (37) 13 (36) 28 (51) 19 (26) 0.018
Her2 64 (39) 1 (3) 11 (20) 52 (72) o0.001
Bcl-2 105 (64) 33 (92) 46 (84) 26 (36) o0.001
p53 42 (26) 0 7 (13) 35 (49) o0.001
E-cadherin 163 (100) 36 (100) 55 (100) 72 (100) —
EGFR 0 0 0 0 —
IGFR 157 (96) 35 (97) 54 (98) 68 (94) 0.513
Keratin 5/6 3 (2) 0 0 3 (4) 0.145
Keratin 14 0 0 0 0 —
S100 0 0 0 0 —
Keratin 19 162 (99) 35 (97) 55 (100) 72 (100) 0.170
EMA 162 (99) 36 (100) 55 (100) 71 (99) 0.529
CA125 0 0 0 0 —
CD31 0 0 0 0 —
AR¼androgen receptor; DCIS¼ductal carcinoma in situ;E G F R ¼epidermal growth factor receptor; EMA¼epithelial membrane antigen; ER¼oestrogen receptor;
IGFR¼insulin-like growth factor receptor; PR¼progesterone receptor. Values in parentheses are percentages.
Mixed Her2-positive 
Luminal (predominantly ER-positive, Bcl-2 positive)
AR-positive Mixed
Nonluminal (predominantly ER-negative, Bcl-2 negative)
AR-negative
p53
Her2 
PR 
ER
Bcl-2 
AR
Grade
Figure 1 Two-dimensional unsupervised hierarchical cluster diagram (average linkage) of data consisting of 978 genes by 163 ductal carcinoma in situ
samples. Clustergram of six markers and distribution of histological grade. Each column indicates a single case; each row, a single immunomarker. Green (or
light grey), negative immunostaining; red (or dark grey), positive immunostaining; white, well-differentiated lesion; grey, intermediately differentiated lesion;
black, poorly differentiated lesion. The dendrogram shows the relatedness of the immunoprofiles of individual cases and suggests two major groups, which
are further subdivided into subgroups.
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basal-like type lesions. Mixed lesions from the Perou et al (2000)
classification frequently showed ER and Bcl-2 marker expression.
DISCUSSION
The traditional histological classification of invasive breast cancer
tumours has been debated by results from gene expression arrays
leading to the molecular categorisation of breast cancer into
luminal and nonluminal tumours (Perou et al, 2000). As invasive
ductal breast cancers develop via the noninvasive precursor DCIS,
these lesions may be categorised in the same way. Most similarities
were found among the different stages of breast tumour
progression, and it was suggested that gene expression alterations
conferring the potential for invasive growth are already present in
the preinvasive stadium of breast cancer (Ma et al, 2003). It has
been shown that the molecular subgroups of invasive carcinoma
can be distinguished using a set of IHC markers (Makretsov et al,
2004). In addition, response to treatment is subgroup dependent
(Carey et al, 2007). Using IHC, our analysis focused on the
identification of subgroups in pure DCIS, to improve insight into
the different pathways of tumour development, and to produce a
classification of DCIS based on marker expression. Sixteen
markers were selected to distinguish luminal and nonluminal cell
differentiation, or because of their reported value to differentiate
DCIS. Unsupervised hierarchical analysis, like in the evaluation of
gene expression arrays, was performed to categorise DCIS. Ten
markers were either positive or negative in nearly all DCISs and
therefore not useful for classification.
Oestrogen receptor, PR, AR, Her2, Bcl-2, and p53 were used for
IHC classification of DCIS. Oestrogen receptor, PR, and AR were
positive in 68, 46 and 37% of the patients in our series,
respectively. Others found ER, PR, and AR expression in 54–73,
49–61, and 33–44%, respectively (Selim et al, 2002; Baqai and
Shousha, 2003; Barnes et al, 2005; Rody et al, 2005). We further
found that well- and intermediately differentiated DCISs were
predominantly ER positive and PR positive, while poorly
differentiated DCIS usually lacked steroid receptor expression
and was correlated with Her2 overexpression. This finding became
further evident by the unsupervised hierarchical clustering results
that clearly divided DCIS into luminal and nonluminal lesions. The
luminal-type DCIS was further divided into an AR-positive and
AR-negative subtype.
Bcl-2, involved in apoptosis, was present in 64% of all DCISs,
while p53 was expressed in 26% of the cases in our series. These
findings are in correspondence with results from others who
reported Bcl-2 and p53 expression in 76 and 24% of DCIS cases,
respectively (Siziopikou et al, 1996). The Bcl-2-positive/p53-
negative phenotype, which is similar to normal epithelium and
benign lesions, was observed in 95 cases originating from the
luminal clusters. This phenotype might reflect a more favourable
group of lesions.
Androgen receptor expression was most frequently seen in
intermediately and well-differentiated DCIS (P¼0.018) in our
series of patients. Not many studies investigated AR in DCIS.
Moinfar et al (2003) reported a higher rate of AR expression in
especially low-grade DCIS as opposed to high-grade DCIS,
although others did not find a correlation between AR expression
and grade (Selim et al, 2002). Androgen receptor-positive breast
cancer patients have prolonged survival and a better response to
hormonal treatment than AR-negative patients.
Within the nonluminal type, a Her2-positive/ER-negative
subtype with 91% poorly differentiated DCISs could be identified.
Her2 is known to be amplified and/or overexpressed in invasive
breast cancer in 10–30% of cases and associated with poor
outcome (Ravdin and Chamness, 1995; Tsuda, 2001). The absence
of Her2 overexpression in normal ducts and atypical ductal
hyperplasia, and the frequent of Her2 amplification found in DCIS
suggests that Her2 alterations are an early event in the pathway of
development of Her2-positive invasive carcinomas. In our study,
39% of the cases were positive for Her2. The higher frequency of
Her2-positive lesions in DCIS compared with invasive breast
cancer has been argued to occur due to loss of expression;
however, it might indicate that in the breast cancer progression
model, there may be lesions that do not frequently evolve into
invasive breast cancers, including Her2-positive DCIS lesions.
Moreover, the mammographic detection of poorly differentiated
Table 3 Distribution of markers and histological grade among cluster group after unsupervised hierarchical clustering analysis with six markers (ER, PR,
AR, Bcl-2, Her2, and p53)
Distribution of markers and grade by group and subgroup
Luminal group Nonluminal group P
a
Total
AR-positive
subgroup
AR-negative
subgroup
Mixed
subgroup Total
Her2-positive
subgroup
Mixed
subgroup
Two
groups Subgroups
Number of patients 107 (66) 33 (20) 40 (25) 34 (21) 56 (34) 34 (21) 22 (14)
Markers
ER 106 (99) 33 (100) 39 (98) 34 (100) 5 (9) 0 5 (23) o0.001 o0.001
PR 73 (68) 30 (91) 40 (100) 3 (9) 2 (4) 2 (6) 0 o0.001 o0.001
AR 45 (42) 33 (100) 0 12 (35) 15 (27) 0 15 (68) 0.055 o0.001
Bcl-2 103 (96) 30 (91) 39 (98) 34 (100) 2 (4) 1 (3) 1 (5) o0.001 o0.001
Her2 18 (17) 6 (18) 6 (15) 6 (18) 46 (82) 34 (100) 12 (55) o0.001 o0.001
p53 9 (8) 0 0 9 (27) 33 (59) 20 (59) 13 (59) o0.001 o0.001
Grade
Well 34 (32) 11 (33) 15 (38) 8 (24) 2 (4) 1 (3) 1 (5) 0.190
b 0.474
b
Intermediate 46 (43) 17 (52) 16 (40) 13 (38) 9 (16) 2 (6) 7 (32)
Poor 27 (25) 5 (15) 9 (23) 13 (38) 45 (80) 31 (91) 14 (64) o0.001
c o0.001
c
AR¼androgen receptor; DCIS¼ductal carcinoma in situ;E R ¼oestrogen receptor; PR¼progesterone receptor. Values in parentheses are percentages.
aw
2-test.
bIntermediately differentiated DCIS vs well-differentiated DCIS.
cIntermediately differentiated DCIS vs poorly differentiated DCIS.
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conspicuous microcalcifications.
Basal-like carcinomas have been identified in gene expression
profiling studies as a subtype of invasive breast cancer. These
lesions are ER negative, PR negative, and Her2 negative (triple
negative). We found eight (5%) triple-negative lesions. Four of
them were poorly differentiated. Bryan et al (2006) studied 66
cases of high nuclear grade DCIS to determine the frequency of the
triple-negative phenotype and showed that only four cases (6%)
exhibited the triple-negative phenotype. In contrast with our
results, they found EGFR expressed in all four triple-negative
lesions and also in a selection of nontriple-negative lesions,
while we found negative staining in all lesions. In addition,
they observed more frequent expression of keratins 5/6 and 14
compared with our series. This could be a result of the
interobserver variability, since our cutoff point was more than
10% strong membraneous staining, while Bryan et al (2006)
considered any staining as positive. Recently, (Livasy et al (2007)
found 8% basal-like subtypes in a population-based series of 245
patients. Given that invasive breast cancers typically share
immunophenotypic features with the DCIS lesion from which
they arise, these findings corroborate the possibility that the triple-
negative DCIS lesions represent a precursor lesion to invasive
basal-like carcinomas. In these (medullary-like and metaplastic)
carcinomas, in situ components are usually minor or absent,
suggesting a rapid progression from in situ to the invasive stage.
This is in keeping with the absence of basal-like in situ lesions in
preventive mastectomy specimens of BRCA1 carriers, which are
prone to develop basal-like tumours (Hoogerbrugge et al, 2003).
Clustering analysis showed that the well-differentiated DCIS and
intermediately differentiated DCIS share IHC features among the
different clusters. It seems that intermediately differentiated DCIS
shows more resemblance with well-differentiated DCIS as com-
pared with poorly differentiated DCIS. A recent study from our
institute investigating classification of DCIS by gene expression
profiling confirms this finding and identified luminal, Her2-, and
basal-like tumours in a series of 40 DCIS lesions (Hannemann
et al, 2006). A classification of DCIS by IHC might identify
identical groups of luminal and nonluminal tumours, which can be
further subdivided, reflecting the heterogeneous nature of DCIS.
Therefore, IHC can assist in objectivation of variations in
morphologic tumour classification of DCIS.
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Nonluminal, Her2  (well/intermediate/poor) 0 0 0 7 (1/2/4) 0 7 (1/2/4)
Mixed (well/intermediate/poor) 2 (1/1/0) 5 (0/2/3) 1 (0/0/1) 1 (0/1/0) 3 (0/1/2) 12 (1/5/6)
Total (well/intermediate/poor) 63 (26/31/6) 21 (0/7/14) 43 (1/4/38) 8 (1/3/4) 28 (8/10/10) 163 (36/55/72)
AR¼androgen receptor; ER¼oestrogen receptor; IHC¼immunohistochemistry; PR¼progesterone receptor.
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